Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Prostatic Neoplasms 3Leukemia 3Hematologic Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, B-Cell 2Lung Neoplasms 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sleep Initiation and Maintenance Disorders 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nose Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Paclitaxel 9Carboplatin 6Cisplatin 5Hyperthermic Intraperitoneal Chemotherapy 4Oxaliplatin 3Fluorouracil 3Cytoreduction Surgical Procedures 3Bevacizumab 3nintedanib 2Mitomycin 2Leucovorin 2Laparoscopy 2Gemcitabine 2Folfox protocol 2Docetaxel 2vandetanib 1talimogene laherparepvec 1strattice 1sodium thiosulfate 1poly(I).poly(c12,U) 1pembrolizumab 1olaparib 1nilotinib 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1farletuzumab 1enzastaurin 1catumaxomab 1birinapant 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Peritoneal Neoplasms × Electrocardiography × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡